EC Signs Agreement for Additional Doses of Gilead’s Covid-19 Drug

Published : 16 Oct 2020

Drug Name: remdesivir

The European Commission (EC) has inked a joint procurance agreement (JPA) with Gilead Sciences for the availability of up to five hundred,000 treatment courses of the company’s Covid-19 drug, Veklury (remdesivir).

The JPA involves thirty-six participants, together with all countries within the European Community (EU), the ECU Economic space (EEA), and the UK, in conjunction with six candidate countries and potential candidates.

With this deal, all the collaborating countries can get Velkury, an ester analog, directly from Gilead for period demand and additionally reposition.

While the agreement covers purchases over the approaching six months, it comes with an associate degree possibility for extension.

Velkury is presently the sole drug within the EU to carry conditional promoting authorization, granted on three July, for Covid-19 patients World Health Organization need chemical element offer.

The authorization derives from the results of the ACTT-1 trial. the information from the irregular, double-blind, placebo-controlled trial showed clinical effectuality and safety of Veklury in Covid-19 patients with respiratory disorder needing supplemental chemical element.

Also, the submission was backed by results from 2 irregular trials showing the effectuality and safety of Veklury in five-day and ten-day dosing durations.

This deal follows the EC’s €70m contract with Gilead for thirty-three,380 doses of Veklury that are distributed across the EU, and also the GB since August.

These doses were expected to last from August through Oct, however a rise in demand diode to the newest agreement.

European Commission Health and Food Safety commissioner painter Kyriakides said: “Today we tend to secure access to Remdesivir for the treatment of up to five hundred,000 patients in want.

“Through our EU Joint Procurements, we tend to square measure empowering countries across Europe to hitch forces and acquire access to important instrumentality and medicines.”

Gilead expects the availability of Veklury to fulfill international demand by the tip of this month. the corporate plans to manufacture over 2 million treatment courses of the drug this year, boosting offer by quite 400-fold since Gregorian calendar month.

If needed, Gilead can manufacture many million a lot of treatment courses next year.

Source: GlobalData.com